scholarly journals The role of hypofractionated radiotherapy for the definitive treatment of localized prostate cancer: early results of a randomized trial

2019 ◽  
Vol 10 (25) ◽  
pp. 6217-6224
Author(s):  
Petros Alexidis ◽  
Dimitris Dragoumis ◽  
Sotirios Karatzoglou ◽  
Konstantinos Drevelegas ◽  
Ioannis Tzitzikas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Randomized Trial ◽  
Localized Prostate Cancer ◽  
Hypofractionated Radiotherapy ◽  
Definitive Treatment ◽  
Early Results

scholarly journals Late results of a randomized trial on the role of mild hypofractionated radiotherapy for the treatment of localized prostate cancer

2020 ◽  
Vol 11 (5) ◽  
pp. 1008-1016
Author(s):  
Petros Alexidis ◽  
Sotirios Karatzoglou ◽  
Dimitris Dragoumis ◽  
Konstantinos Drevelegas ◽  
Ioannis Tzitzikas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Randomized Trial ◽  
Late Results ◽  
Localized Prostate Cancer ◽  
Hypofractionated Radiotherapy

Comparison of conventionally fractionated and hypofractionated schedule for post-prostatectomy salvage radiotherapy: Early results from non-randomized observational study.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. e551-e551
Author(s):  
Jure Murgic ◽  
Blanka Jaksic ◽  
Ivan Kruljac ◽  
Marin Prpic ◽  
Mirjana Budanec ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Side Effects ◽  
Hormonal Therapy ◽  
Cox Proportional Hazards Model ◽  
Hypofractionated Radiotherapy ◽  
Definitive Treatment ◽  
Early Results ◽  
Significant Difference ◽  
Conventionally Fractionated

e551 Background: Data on hypofractionated radiotherapy in definitive treatment of prostate cancer are maturing; however, limited information is available for hypofractionated radiotherapy after prostatectomy. We aimed to compare hypofractionated and conventionally fractionated radiotherapy in salvage setting for biochemically recurrent prostate cancer. Methods: A retrospective analysis was performed in 106 patients with proven PSA recurrence treated to the prostate bed. Patients were non-randomly, in a alternating fashion, subjected to either 52.5 Gy in 20 fractions of 2.625 Gy over 4 weeks (N = 57, hypofractionated group) or 66 Gy in 33 fractions of 2 Gy over 6.5 weeks (N = 49, conventionally fractionated group). There was no statistically significant difference in pathologic T-stage and Gleason score distribution between the groups. In the conventionally fractionated group there were more patients with positive margins (p = 0.01), more prevalent concomitant hormonal therapy (50.9% vs 61.2%, p = 0.001), but less long-term hormonal therapy (21.4% vs 81%, p < 0.001), compared to hypofractionated group. Median follow-up was 20 months (range 6-36 months). Failure (PSA nadir+0.2) rates between the groups were compared using Cox proportional hazards model. Radiation-related side-effects were assessed using RTOG scoring scale. Results: At this early point, 13 patients (22.8%), and 6 patients (12.2%) experienced treatment failure in the hypofractionated group and conventionally fractionated group, respectively (HR 3.1, 95%CI (1.5-6.3)). More late grade 2 gastrointestinal and genitourinary side-effects were observed in conventionally fractionated group (4.1% vs 1.8%, and 2% vs 0%, p = 0.01, respectively). No grade 3 toxicities were observed. Conclusions: More initial biochemical failures were observed in hypofractionated group compared to conventionally fractionated group. However, baseline heterogeneity between the groups and short follow-up preclude any causal observation of differential efficacy between these two schedules. Randomized phase II trial is planned to prospectively compare these two regimens.

scholarly journals Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Wei Guo ◽  
Yun-Chuan Sun ◽  
Jian-Qiang Bi ◽  
Xin-Ying He ◽  
Li Xiao
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Adverse Events ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Localized Prostate Cancer ◽  
Hypofractionated Radiotherapy ◽  
Cancer Specific Survival ◽  
Conventional Radiotherapy ◽  
Results Of Treatment

Abstract Background Prostate cancer is one of the most common cancers in the world. The results of treatment after hypofractionated radiotherapy only have been reported from several small randomized clinical trials. Therefore, we conducted a meta-analysis to compare clinical outcomes of hypofractionated radiotherapy versus conventional radiotherapy in the treatment of intermediate- to high-risk localized prostate cancer. Methods Relevant studies were identified through searching related databases till August 2018. Hazard ratio (HR) or risk ratio (RR) with its corresponding 95% confidence interval (CI) was used as pooled statistics for all analyses. Results The meta-analysis results showed that overall survival (HR = 1.12, 95% CI: 0.93–1.35, p = 0.219) and prostate cancer-specific survival (HR = 1.29, 95% CI: 0.42–3.95, p = 0.661) were similar in two groups. The pooled data showed that biochemical failure was RR = 0.90, 95% CI: 0.76–1.07, p = 0.248. The incidence of acute adverse gastrointestinal events (grade ≥ 2) was higher in the hypofractionated radiotherapy (RR = 1.70, 95% CI: 1.12–2.56, p = 0.012); conversely, for late grade ≥ 2 gastrointestinal adverse events, a significant increase in the conventional radiotherapy was found (RR = 0.75, 95% CI: 0.61–0.91, p = 0.003). Acute (RR = 1.01, 95% CI: 0.89–1.15, p = 0.894) and late (RR = 0.98, 95% CI: 0.86–1.10, p = 0.692) genitourinary adverse events (grade ≥ 2) were similar for both treatment groups. Conclusion Results suggest that the efficacy and risk for adverse events are comparable for hypofractionated radiotherapy and conventional radiotherapy in the treatment of intermediate- to high-risk localized prostate cancer.

Role of high-field MR in studies of localized prostate cancer

2013 ◽  
Vol 27 (1) ◽  
pp. 67-79 ◽  
Author(s):  
Miriam W. Lagemaat ◽  
Tom W. J. Scheenen
Keyword(s):  
Prostate Cancer ◽  
High Field ◽  
Localized Prostate Cancer ◽  
High Field Mr

scholarly journals Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries

2021 ◽  
Author(s):  
Mohamed Shelan ◽  
Daniel M. Aebersold ◽  
Clemens Albrecht ◽  
Dirk Böhmer ◽  
Michael Flentje ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Oncology ◽  
Working Party ◽  
Phase Iii ◽  
Localized Prostate Cancer ◽  
Definitive Treatment ◽  
Cancer Society ◽  
Fractionation Schedule ◽  
German Speaking ◽  
Moderate Hypofractionation

Abstract Purpose Various randomized phase III clinical trials have compared moderately hypofractionated to normofractionated radiotherapy (RT). These modalities showed similar effectiveness without major differences in toxicity. This project was conducted by the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society. We aimed to investigate expert opinions on the use of moderately hypofractionated RT as a definitive treatment for localized prostate cancer in German-speaking countries. Methods A 25-item, web-based questionnaire on moderate-hypofractionation RT was prepared by an internal committee. The experts of the DEGRO were asked to complete the questionnaire. Results Fourteen active members of DEGRO completed the questionnaire. The questions described indications for selecting patients eligible to receive moderate hypofractionation based on clinical and pathological factors such as age, urinary symptoms, and risk-group. The questions also collected information on the technical aspects of selection criteria, including the definition of a clinical target volume, the use of imaging, protocols for bladder and rectal filling, the choice of a fractionation schedule, and the use of image guidance. Moreover, the questionnaire collected information on post-treatment surveillance after applying moderately hypofractionated RT. Conclusion Although opinions varied on the use of moderate-hypofractionation RT, the current survey reflected broad agreement on the notion that moderately hypofractionated RT could be considered a standard treatment for localized prostate cancer in German-speaking countries.

Sign in / Sign up

Export Citation Format

Share Document